Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology (DGU 2026) - Oct 15, 2026 - Abstract #V38-02; Pres time: Sep 18, 2026; 10:20 AM - 10:30 AM; Location: Room 19; "52% patients received first-line IO-combinations (IO-IO: 43%, TKI-IO: 57%) and 48% patients TKI-monotherapy, predominantly sunitinib. Subsequent therapy was mostly Cabozantinib (after IO-IO), Lenvatinib/Everolimus (after IO-TKI) or Nivolumab (after TKI mono). Our data suggests that first-line IO-/TKI-based combinations yields higher ORR compared to IO-/IO-based combinations and single agent TKI, but did not translate into an improved PFS or OS."
HEOR • Metastases • Real-world • Real-world evidence • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
P. Paffenholz 1; J. Casuscelli 2; C. Aydogdu 2; S. Zschäbitz 3; E. Rinderknecht 4; A. Mattigk 5; A.-L. People 6; P. Ivanyi 7; T. Hilser 8; C. Darr 9; L. Flegar 10; K. Schlack 11; D. Seidl 12; A. Handke 13; M. Klee 14; T. Nestler 15; M. Rehlinghaus 16; S. Hijazi 17; A. Heidenreich 1; V. Grünwald 8
|